tiprankstipranks
Trending News
More News >
Advertisement
Advertisement

Dong-E-E-Jiao Reports Strong Financial Growth in H1 2025

Story Highlights
Dong-E-E-Jiao Reports Strong Financial Growth in H1 2025

Elevate Your Investing Strategy:

  • Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

China Resources Pharmaceutical Group Ltd. ( (HK:3320) ) has provided an update.

Dong-E-E-Jiao, a subsidiary of China Resources Pharmaceutical Group Ltd., reported its unaudited financial results for the first half of 2025, showing a revenue increase of 11.02% and a net profit rise of 10.74% compared to the previous year. The financial performance indicates a stable growth trajectory, with improvements in net cash flow from operating activities and earnings per share, reflecting positively on the company’s operational efficiency and market positioning.

The most recent analyst rating on (HK:3320) stock is a Buy with a HK$7.50 price target. To see the full list of analyst forecasts on China Resources Pharmaceutical Group Ltd. stock, see the HK:3320 Stock Forecast page.

More about China Resources Pharmaceutical Group Ltd.

China Resources Pharmaceutical Group Ltd. is a company involved in the pharmaceutical industry, with a focus on the production and distribution of pharmaceutical products. The company holds a significant stake in Dong-E-E-Jiao, a subsidiary listed on the Shenzhen Stock Exchange, which specializes in traditional Chinese medicine products.

Average Trading Volume: 11,891,732

Technical Sentiment Signal: Sell

Current Market Cap: HK$33.05B

For a thorough assessment of 3320 stock, go to TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1